Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis by Lindner, Ewald et al.
BioMed CentralBMC Medical Genetics
ssOpen AcceResearch article
Lack of association between the chemokine receptor 5 
polymorphism CCR5delta32 in rheumatoid arthritis and juvenile 
idiopathic arthritis
Ewald Lindner†1, Gry BN Nordang†1, Espen Melum1, Berit Flatø2, 
Anne Marit Selvaag2, Erik Thorsby1, Tore K Kvien3, Øystein T Førre2 and 
Benedicte A Lie*1
Address: 1Institute of Immunology, Rikshospitalet-Radiumhospitalet Medical Center, 0027 Oslo, Norway, 2Department of Rheumatology, 
Rikshospitalet-Radiumhospitalet Medical Center, 0027 Oslo, Norway and 3Department of Rheumatology, Diakonhjemmet Hospital, N-0319 
Oslo, Norway
Email: Ewald Lindner - Ewald.Lindner@student.uibk.ac.at; Gry BN Nordang - g.b.namlos@medisin.uio.no; 
Espen Melum - espen.melum@medisin.uio.no; Berit Flatø - berit.flato@rikshospitalet.no; Anne Marit Selvaag - aselvaag@ulrik.uio.no; 
Erik Thorsby - erik.thorsby@medisin.uio.no; Tore K Kvien - t.k.kvien@medisin.uio.no; Øystein T Førre - o.t.forre@medisin.uio.no; 
Benedicte A Lie* - b.a.lie@medisin.uio.no
* Corresponding author    †Equal contributors
Abstract
Background: The chemokine receptor CCR5 has been detected at elevated levels on synovial T
cells, and a 32 bp deletion in the CCR5 gene leads to a non-functional receptor. A negative
association between the CCR5∆32 and rheumatoid arthritis (RA) has been reported, although with
conflicting results. In juvenile idiopathic arthritis (JIA), an association with CCR5 was recently
reported. The purpose of this study was to investigate if the CCR5∆32 polymorphism is associated
with RA or JIA in Norwegian cohorts.
Methods: 853 RA patients, 524 JIA patients and 658 controls were genotyped for the CCR5∆32
polymorphism.
Results: The CCR5∆32 allele frequency was 11.5% in the controls vs. 10.4% in RA patients (OR =
0.90; P = 0.36) and 9.7% in JIA patients (OR = 0.85; P = 0.20). No decreased homozygosity was
observed for CCR5∆32, as previously suggested.
Conclusion: Our data do not support an association between the CCR5∆32 allele and Norwegian
RA or JIA patients. Combining our results with those from a recently published meta-analysis still
provide evidence for a role for CCR5∆32 in RA, albeit substantially weaker than the effect first
reported.
Background
In rheumatoid arthritis (RA) and juvenile idiopatic arthri-
tis (JIA), the synovium is infiltrated with T cells and mac-
rophages, and chemokine receptors and their ligands are
involved in regulation of the inflammation [1,2]. Chem-
okines regulate lymphocyte trafficking by inducing cell
motility and activating adhesion molecules. The chemok-
ine receptor CCR5 is a G-protein-coupled seven-trans-
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macrophages, memory T-cells and dendritic cells, where it
serves as a receptor for RANTES, MIP-1-α, MIP-1-β and
MCP [3]. CCR5 has functionally been implicated in the
pathogenesis of RA [2] and JIA [4]. The expression of
CCR5 is increased on synovial T cells in patients with JIA
[4] or RA [5].
The gene encoding CCR5 is located on chomosome
3p21.3 [6]. A 32 base pair deletion (CCR5∆32) in the
CCR5 gene leads to a frame shift and a non-functional
receptor. Homozygosity for CCR5∆32 results in a com-
plete lack of surface expression of CCR5 [7]. CCR5 hap-
pens to be a co-receptor for HIV-1 on CD4+ T-cells with
the consequence that CCR5∆32 homozygotes are pro-
tected against infections with HIV-1, while heterozygotes
have a delay in the progression towards AIDS [8]. The
CCR5 deletion is common among Caucasians, especially
in Nordic populations [9], but has not been found in
native Africans, American Indians or East Indian ethnic
groups.
The role of CCR5∆32 has been investigated genetically in
several immune-mediated diseases. In RA, a negative asso-
ciation of the deletion has been reported with divergent
results [10-14], while in childhood arthritis a weak nega-
tive association has been observed in a single study [15].
Regarding clinical outcome, it has been reported that car-
riers of the CCR5∆32 allele occurred at a significantly
higher frequency among patients with non-severe com-
pared to severe disease (N = 160) [14], whereas a later and
larger study of 438 patients did not find any association
between carriage of the CCR5∆32 and milder disease
severity in inflammatory polyarthritis [16]. A recent meta-
analysis of five reports addressing the association of
CCR5∆32 with susceptibility to develop RA in patients of
European ancestry (1790 cases and 2717 controls),
reported a significant negative association and estimated
the deletion to provide disease resistance with an OR =
0.65 (95% CI [0.55–0.77])[17].
The aim of our study was to investigate if there is an asso-
ciation between CCR5∆32 and RA in the largest individual
data set studied so far, as well as to address whether
CCR5∆32 is also associated with JIA, not yet extensively
investigated.
Methods
853 RA patients, 524 JIA patients and 658 controls were
included in the study. The RA patients, admitted to the
Department of Rheumatology, Diakonhjemmet Hospital,
Oslo, Norway, fulfilled the American College of Rheuma-
tology (ACR) criteria [18] and the JIA patients, admitted
to the Department of Rheumatology, Rikshospitalet-Radi-
umhospitalet Medical Center, Oslo, Norway, were classi-
fied according to the ILAR (International League of
Associations for Rheumatology) criteria [19]. The control
group was recruited through the Norwegian Bone Marrow
Registry. All patients and controls were of Norwegian ori-
gin. The study was approved by the Norwegian Regional
Ethics committee, and the participants had given their
informed consent.
Whole-genome amplification was performed on genomic
DNA using the Genomiphi® kit (GE healthcare systems,
Chalfont St. Giles, UK). Amplification of fragment sur-
rounding the deletion was performed with the dye
labelled forward primer 5'-ATCACTTGGGTGGTGGCT-
GTGTTTGCGTCTC and the reverse primer 5'-AGTAGCA-
GATGACCATGACAAGCAGCGGCAG under the
following conditions; denaturation at 94°C for 15 sec-
onds, annealing and extension at 70°C for 15 seconds, 30
cycles and final extension at 70°C for 5 min at a Perkin
Elmer 9700 thermal cycler (Applied Biosystems, Foster
City, CA, USA). Fragment length was determined on an
ABI3730 DNA Analyzer (Applied Biosystems) with subse-
quent allele calling in GeneMapper v3.7 where a 193 bp
PCR product corresponded to the wild type allele and a
161 bp product represented the deletion. Part of the con-
trol material was genotyped in our previous publication
[20].
Statistical power was calculated prior to the study using
the power calculator at [21], assuming the frequency of
10% for the CCR5∆32 and an Odds Ratio of 0.56
(obtained from Zapico et al [14]). The power (at α = 0.05)
was calculated to be 84% for the RA and 75% for the JIA
data set. Allele and genotype frequencies in patients and
controls were compared by the Chi-Square test, or
Fischer's exact test when appropriate, using the Public
Domain Software for Epidemiology and Disease Surveil-
lance EPI Info Version 5 (Center of Disease Control, Epi-
demiology Program Office, Atlanta, GA, USA).
Results and Discussion
The genotype and allele frequencies of CCR5∆32 are sum-
marised in Table 1. The genotyping success rate was >95%
for both the patients and control populations, and all
groups were in Hardy-Weinberg equilibrium. No signifi-
cant negative association was observed with the ∆32 allele
in either RA or JIA (Table 1), and only a negligible devia-
tion in frequency was seen between the patients and con-
trols. Furthermore, no decreased frequency for
homozygosity of ∆32 was evident among the patients
(0.9% in RA, 0.6% in JIA and 1.0% in controls). A revised
meta-analysis, calculated by adding our results to those
from the recently published meta-analysis of pooled RA
cases and controls [17], reduced the initial published risk
estimate from OR = 0.65; 95% CI [0.55–0.77], p < 0.0001,
to OR = 0.83; 95% CI [0.73–0.95], p = 0.0068.Page 2 of 5
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controls investigated to date, do not support the existence
of a negative association between CCR5∆32 and disease
(OR = 0.90; 95% CI [0.71–1.14]). Neither was the pro-
posed disease resistance provided by homozygosity of the
deletion sustained in our data set. The frequency of
CCR5∆32 in our control population is in the same range
as that observed in other European populations and is
highly similar to that reported in a Danish population
[11]. CCR5∆32 has been found to have its highest preva-
lence among Nordic populations [9], which from a statis-
tical power perspective should favour detection of a
negative association in our Norwegian cohort, on the
other hand deviating results between populations for dis-
ease associated alleles is not uncommon, e.g. for PADI4
[22-25].
Altogether, two studies suggest an association between
CCR5∆32 and RA [13,14], while three studies [10-12], in
addition to ours, do not reveal statistical significant evi-
dence to support this. The number of patients included in
the positive studies was 160 and 516 whereas in the neg-
ative studies 278, 163, 673 and 853 patients were ana-
lysed. A weak effect of CCR5∆32 on the disease risk,
combined with inadequate power, could explain the con-
tradictory results. Alternatively, there could be true differ-
ences between the populations in the effect exercised by
CCR5; i.e. due to genetic or allelic heterogeneity, variable
influence of environmental factors, gene-gene interaction,
or variable linkage disequilibrium patterns. All studies
display a deviation in the direction of a lower frequency
for the deletion among RA patients, but in our data set
only a 0.9% reduction in frequency was seen in RA
patients compared to controls. The results of a recent
meta-analysis of pooled cases and controls were in favour
of a negative association (OR = 0.65 (95% CI [0.55–
0.77])). [17]. We recalculated the power of our RA study
post hoc based on the odds ratio for the CCR5∆32
obtained in the recent meta-analysis [17], and given this
risk effect our power was reduced to 63%. When our RA
data set was included in a revised meta-analysis, the over-
all risk estimate was greatly reduced (OR = 0.83; 95% CI
[0.73–0.95, p = 0.0068]). Furthermore, if the true risk esti-
mate is in the range of that calculated after also including
our data into the pooled meta-analysis, one would need
almost 4000 cases and an equal amount of controls to
replicate the finding with an 80% power. Notably, the
CCR5∆32 meta-analysis may also have been prone to type
1 error caused by e.g. publication bias or heterogeneity
between the populations included in the combined anal-
ysis [26].
Our data does not reveal an association in JIA. After the
initiation of our study, the possible association of CCR5
in JIA was addressed, and the authors reported a negative
association between CCR5∆32 and childhood arthritis,
particularly in the early onset group and in those diag-
nosed with pauciarticular subtype [15]. This finding was
not sustained in our data set as no association was
revealed when stratifying for either JIA subgroups, includ-
ing the oligoarthirits patients (comparable to the pauci-
articular group defined by the ACR criterias; OR = 0.80,
95% CI [0.54–1.17], p = 0.23), or early disease onset (<6
years; OR = 0.81, 95% CI [0.55–1.19], p = 0.27). Further
investigations are warranted for JIA before any firm con-
clusions can be drawn. Nevertheless, our study does not
suggest that CCR5∆32 influences the risk of JIA, and if
present the effect is likely to be small.
CCR5 has functionally been implicated in RA, and our
study does not formally exclude CCR5 as a candidate gene
for RA and JIA. Polymorphisms located elsewhere in the
gene could potentially be predisposing, and if the associ-
ations observed for ∆32 is only secondary due to linkage
disequilibrium, that could be an explanation for the dis-
crepant results obtained by different studies. Interestingly,
in the recently reported childhood arthritis study [15]
other polymorphisms in the CCR5 gene were also investi-
gated, and an additional association with the CCR5 -
1835T allele was also observed. No strong linkage dise-
Table 1: CCR5 genotype and allele frequencies among controls, RA patients and JIA patients
Controls no. (%) RA no. (%) OR (95% CI) p JIA no. (%) OR (95% CI) p
CCR5 genotype
∆32/∆32 6 (0.9) 9 (1.0) 1.13 (0.43–2.98) 0.81 3 (0.6) 0.67 (0.20–2.31) 0.53
∆32/wt 136 (21.1) 156 (18.7) 0.86 (0.66–1.11) 0.24 93 (18.1) 0.83 (0.62–1.11) 0.20
wt/wt 503 (78.0) 671 (80.3) 1.15 (0.89–1.48) 0.28 419 (81.4) 1.23 (0.92–1.64) 0.16
CCR5 allele
∆32 148 (11.5) 174 (10.4) 0.90 (0.71–1.13) 0.35 99 (9.7) 0.82 (0.63–1.07) 0.15
wt 1142 (88.5) 1498 (89.6) 931 (90.4)
RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; N: number of individuals/chromosomes with the denoted genotype/allele; OR (95% CI): 
Odds ratio with corresponding 95% confidence interval; wt: wild type; ∆32: 32 bp deletion.Page 3 of 5
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but the haplotype lacking both these alleles displayed
positive association, which could suggest that the true eti-
ological variant of CCR5 in RA or JIA pathogenesis that is
still unidentified.
Conclusion
In conclusion, whether the CCR5 gene is involved in RA
or JIA susceptibility remains unclear, however, our study
suggests that if a protective effect is exercised by CCR5∆32,
it is minor and less than predicted from the meta-analysis
of previous publications[17].
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